Trials / Completed
CompletedNCT03877562
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of CORT118335 on Olanzapine-Induced Weight Gain in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Corcept Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate if there is any difference in the amount of weight gained by participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy test medicine which looks like CORT118335 but contains no active medicine). Safety and tolerability of CORT118335 when taken with olanzapine will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine | Olanzapine 10 mg oral tablet |
| DRUG | CORT118335 | CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets |
| DRUG | Placebo | Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2020-03-13
- Completion
- 2020-03-25
- First posted
- 2019-03-15
- Last updated
- 2020-04-28
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03877562. Inclusion in this directory is not an endorsement.